There is a critical gap in evidence regarding whether different treatment strategies early in relapsing multiple sclerosis prevent long-term disability, especially if a more aggressive treatment approach is warranted from the time of diagnosis, or if early escalation after a suboptimal treatment response to first-line therapies is adequate. Recent observational studies are providing a window into what may happen to people with MS years later with different treatments.